Siemens TNIH assay with 0/3 h absolute troponin delta cut-offs (95% confidence intervals in parentheses)
| . | Absolute troponin delta at <3 ng/L . | Absolute troponin delta at <7 ng/L . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 87.4% (79.7–92.9) | 86.8% (79.2–92.4) | 84.7% (76.6–90.8) | 83.3% (75.2–89.7) |
| Specificity | 88.6% (86.0–90.8) | 88.8% (86.2–91.1) | 93.6% (91.5–95.3) | 93.8% (91.7–95.4) |
| PPV | 55.1% (49.7–60.5) | 56.3% (50.7–61.6) | 68.1% (59.6–75.8) | 68.8% (60.4–76.4) |
| NPV | 97.8% (96.4–98.6) | 97.6% (96.2–98.5) | 97.4% (95.9–98.5) | 97.1% (95.6–98.3) |
| . | Absolute troponin delta at <3 ng/L . | Absolute troponin delta at <7 ng/L . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 87.4% (79.7–92.9) | 86.8% (79.2–92.4) | 84.7% (76.6–90.8) | 83.3% (75.2–89.7) |
| Specificity | 88.6% (86.0–90.8) | 88.8% (86.2–91.1) | 93.6% (91.5–95.3) | 93.8% (91.7–95.4) |
| PPV | 55.1% (49.7–60.5) | 56.3% (50.7–61.6) | 68.1% (59.6–75.8) | 68.8% (60.4–76.4) |
| NPV | 97.8% (96.4–98.6) | 97.6% (96.2–98.5) | 97.4% (95.9–98.5) | 97.1% (95.6–98.3) |
| . | Relative troponin delta at <20% . | Relative troponin delta at <50% . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 70.3% (60.9–78.6) | 70.2% (60.9–78.4) | 58.6% (48.8–67.8) | 57.9% (48.3–67.1) |
| Specificity | 53.6% (49.8–57.3) | 53.65 (49.8–57.4) | 74.1% (70.7–77.3) | 74.1% (70.7–77.4) |
| PPV | 19.6% (15.8–23.8) | 20.1% (16.2–24.3) | 26.6% (21.2–32.7) | 27.1% (21.6–33.1) |
| NPV | 91.8% (88.7–94.3) | 91.6% (88.4–94.1) | 91.8% (89.2–93.9) | 91.4% (88.8–93.6) |
| . | Relative troponin delta at <20% . | Relative troponin delta at <50% . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 70.3% (60.9–78.6) | 70.2% (60.9–78.4) | 58.6% (48.8–67.8) | 57.9% (48.3–67.1) |
| Specificity | 53.6% (49.8–57.3) | 53.65 (49.8–57.4) | 74.1% (70.7–77.3) | 74.1% (70.7–77.4) |
| PPV | 19.6% (15.8–23.8) | 20.1% (16.2–24.3) | 26.6% (21.2–32.7) | 27.1% (21.6–33.1) |
| NPV | 91.8% (88.7–94.3) | 91.6% (88.4–94.1) | 91.8% (89.2–93.9) | 91.4% (88.8–93.6) |
AMI, acute myocardial infarction; MACE, major adverse cardiac events; NPV, negative predictive value; PPV, positive predictive value.
Siemens TNIH assay with 0/3 h absolute troponin delta cut-offs (95% confidence intervals in parentheses)
| . | Absolute troponin delta at <3 ng/L . | Absolute troponin delta at <7 ng/L . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 87.4% (79.7–92.9) | 86.8% (79.2–92.4) | 84.7% (76.6–90.8) | 83.3% (75.2–89.7) |
| Specificity | 88.6% (86.0–90.8) | 88.8% (86.2–91.1) | 93.6% (91.5–95.3) | 93.8% (91.7–95.4) |
| PPV | 55.1% (49.7–60.5) | 56.3% (50.7–61.6) | 68.1% (59.6–75.8) | 68.8% (60.4–76.4) |
| NPV | 97.8% (96.4–98.6) | 97.6% (96.2–98.5) | 97.4% (95.9–98.5) | 97.1% (95.6–98.3) |
| . | Absolute troponin delta at <3 ng/L . | Absolute troponin delta at <7 ng/L . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 87.4% (79.7–92.9) | 86.8% (79.2–92.4) | 84.7% (76.6–90.8) | 83.3% (75.2–89.7) |
| Specificity | 88.6% (86.0–90.8) | 88.8% (86.2–91.1) | 93.6% (91.5–95.3) | 93.8% (91.7–95.4) |
| PPV | 55.1% (49.7–60.5) | 56.3% (50.7–61.6) | 68.1% (59.6–75.8) | 68.8% (60.4–76.4) |
| NPV | 97.8% (96.4–98.6) | 97.6% (96.2–98.5) | 97.4% (95.9–98.5) | 97.1% (95.6–98.3) |
| . | Relative troponin delta at <20% . | Relative troponin delta at <50% . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 70.3% (60.9–78.6) | 70.2% (60.9–78.4) | 58.6% (48.8–67.8) | 57.9% (48.3–67.1) |
| Specificity | 53.6% (49.8–57.3) | 53.65 (49.8–57.4) | 74.1% (70.7–77.3) | 74.1% (70.7–77.4) |
| PPV | 19.6% (15.8–23.8) | 20.1% (16.2–24.3) | 26.6% (21.2–32.7) | 27.1% (21.6–33.1) |
| NPV | 91.8% (88.7–94.3) | 91.6% (88.4–94.1) | 91.8% (89.2–93.9) | 91.4% (88.8–93.6) |
| . | Relative troponin delta at <20% . | Relative troponin delta at <50% . | ||
|---|---|---|---|---|
| . | AMI . | 30-Day MACE . | AMI . | 30-Day MACE . |
| Sensitivity | 70.3% (60.9–78.6) | 70.2% (60.9–78.4) | 58.6% (48.8–67.8) | 57.9% (48.3–67.1) |
| Specificity | 53.6% (49.8–57.3) | 53.65 (49.8–57.4) | 74.1% (70.7–77.3) | 74.1% (70.7–77.4) |
| PPV | 19.6% (15.8–23.8) | 20.1% (16.2–24.3) | 26.6% (21.2–32.7) | 27.1% (21.6–33.1) |
| NPV | 91.8% (88.7–94.3) | 91.6% (88.4–94.1) | 91.8% (89.2–93.9) | 91.4% (88.8–93.6) |
AMI, acute myocardial infarction; MACE, major adverse cardiac events; NPV, negative predictive value; PPV, positive predictive value.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
